Proposed new diagnostic criteria for ms in people with a typical demyelinating syndrome from dr. Aaron miller and others. #AANAM

First speaker at #ABN2025 highlighting the current inequity in access to idebenone for Lebers Hereditary Optic Neuropathy across the UK. NICE are due to publish guidance on this in Sept 25

Interesting to see the experience of the Birmingham team of using tocilizimab in small case series of refractory status. Asking if the drug should be included in protocols #ABN2025

Faye Windsor, heart failure specialist pharmacist, plays a vital role in our heart failure service, supporting patients across both hospital and community settings. Find out more about her role this #HeartFailureAwarenessWeek. ➡️ intranet.imperial.nhs.uk/page/18480

This growth in available drug therapy is why there are now pharmacists Association of British Neurologists ! #neuropharmacy

Joela Mathews & Ray Dorsey showcasing their poster Association of British Neurologists demonstrating the role of neuropharmacists in supporting neurology services #ABN2025 #neuropharmacy

Talks this afternoon appraising new therapies. First up, an assesment of CGRP therapies by Prof Loder. Acknowledging the modest (underwhelming?) benefits of CGRPs and the newer PACAP molecules #ABN2025

Fantastic talk by Paresh Malhotra describing the history and current controversies around new treatments for Alzheimer’s. Lots of opportunities for pharmacists to support in the implementation of (if/when available!) Association of British Neurologists UKCPA Neurosciences Committee #ABN2025

Data on tolebrutinib in the HECULES trial for progressive MS. There was a modest benefit in reducing disability progression and increasing disability improvement and improvement of walking speed. There was no benefit in hand function as measured by the 9 hole peg test.

Important to see this published: tinyurl.com/3skcvyn7. Through a UK wide collaboration (including Ruth Dobson Wallace Brownlee Ray Dorsey amongst others) we demonstrated discordance between the JCV testing available with biosimilar Natalizumab versus originator Natalizumab.

Around 50% of people with a negative JCV index on originator Natalizumab JCV antibody testing, became positive on the biosimilar assay. This had a significant impact on patients and the systems they use. Reassuringly, sensitivity was not an issue (98.8%).

So excited to be teaching on the Neuropharmacist masterclass! An awesome opportunity as a previous delegate. Let’s go! Neurology Academy South Tees Hospitals Pharmacy Department

Today the most neuropharmacist in a room for a while. Learning together on Parkinson’s. Sharing information on device development projects and quality improvement across the nhs and involving neuropharmacists. So much has changed over the years Neurology Academy

We are kicking off the Neuropharmacy Masterclass hearing from Viv Horton & Dr Archibald about all things Parkinson’s Neurology Academy Neuropharmacists

Wrapped up today with a fantastic poster session. Delegates presented a range of fantastic audit and service development projects undertaken in their neurology services Neurology Academy Neuropharmacists UKCPA Neurosciences Committee Joela Mathews

Massive congratulations - Neuropharmacist Masterclass project winners Emma and Tyler! Neurology Academy South Tees Hospitals Pharmacy Department

Started the day with a 5k! Neurology Academy All ready for a day of learning on epilepsy #neuropharmacy Neuropharmacists

Today at the Neuropharmacy academy we have a masterclass on epilepsy delivered by Dr Stephen Auger Neurology Academy Neuropharmacists

Pharmacy technicians and pharmacists – have you seen our email about the MHRAgovuk valproate Drug Safety Update and updated safety and educational materials? You can also find this on our website >> tinyurl.com/zfrp3aay

We've just completed our 3rd #Neuropharmacy MasterClass, where delegates presented the outcomes of their workplace projects. Inspiring to see such dedication to improving services and patient care in local settings! Read more: eu1.hubs.ly/H0mnGSs0 Neuropharmacists